Immuron Limited Reports 5% Increase in Global H1 Sales

Reuters

01/19

Immuron Limited Reports 5% Increase in Global H1 Sales

Immuron Limited has reported continued sales growth for the first half (H1) of the fiscal year. Global H1 sales reached AUD$4.2 million, an increase of 5% compared to the prior comparative period (pcp). Second quarter (Q2) global sales were AUD$2.2 million, up 11% on the previous quarter. In Australia, H1 sales totaled AUD$3.3 million, up 13% on pcp, with Q2 sales of AUD$1.7 million, an 11% increase on the prior quarter. The company also launched ProIBS® in Australia during this period. In the USA, H1 sales were AUD$0.9 million, representing a 17% increase on pcp, with Q2 sales of AUD$0.4 million, up 8% from the previous quarter. Canadian H1 sales were AUD$56 thousand, down 85% on pcp, but Q2 sales rose to AUD$42 thousand, an increase of 191% on the prior quarter. Immuron anticipates further growth in Canada with the upcoming launch of Travelan® in Jean Coutu pharmacies in Quebec.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9627699-en) on January 19, 2026, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2604801571"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2604801571\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2604801571?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-19 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604801571","market":"us","top_or_hot":-1,"title":"Immuron Limited Reports 5% Increase in Global H1 Sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immuron Limited Reports 5% Increase in Global H1 Sales\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immuron Limited has reported continued sales growth for the first half (H1) of the fiscal year. Global H1 sales reached AUD$4.2 million, an increase of 5% compared to the prior comparative period (pcp). Second quarter (Q2) global sales were AUD$2.2 million, up 11% on the previous quarter. In Australia, H1 sales totaled AUD$3.3 million, up 13% on pcp, with <a href=\"https://laohu8.com/S/QTWO\">Q2</a> sales of AUD$1.7 million, an 11% increase on the prior quarter. The company also launched ProIBS® in Australia during this period. In the USA, H1 sales were AUD$0.9 million, representing a 17% increase on pcp, with Q2 sales of AUD$0.4 million, up 8% from the previous quarter. Canadian H1 sales were AUD$56 thousand, down 85% on pcp, but Q2 sales rose to AUD$42 thousand, an increase of 191% on the prior quarter. Immuron anticipates further growth in Canada with the upcoming launch of Travelan® in Jean Coutu pharmacies in Quebec.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9627699-en) on January 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immuron Limited Reports 5% Increase in Global H1 Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuron Limited Reports 5% Increase in Global H1 Sales\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-01-19 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immuron Limited Reports 5% Increase in Global H1 Sales\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immuron Limited has reported continued sales growth for the first half (H1) of the fiscal year. Global H1 sales reached AUD$4.2 million, an increase of 5% compared to the prior comparative period (pcp). Second quarter (Q2) global sales were AUD$2.2 million, up 11% on the previous quarter. In Australia, H1 sales totaled AUD$3.3 million, up 13% on pcp, with <a href=\"https://laohu8.com/S/QTWO\">Q2</a> sales of AUD$1.7 million, an 11% increase on the prior quarter. The company also launched ProIBS® in Australia during this period. In the USA, H1 sales were AUD$0.9 million, representing a 17% increase on pcp, with Q2 sales of AUD$0.4 million, up 8% from the previous quarter. Canadian H1 sales were AUD$56 thousand, down 85% on pcp, but Q2 sales rose to AUD$42 thousand, an increase of 191% on the prior quarter. Immuron anticipates further growth in Canada with the upcoming launch of Travelan® in Jean Coutu pharmacies in Quebec.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9627699-en) on January 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nNDL6pKhxb:1","article_id":"2604801571","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604801571","pubTimestamp":1768820419,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immuron Limited has reported continued sales growth for the first half  of the fiscal year. Global H1 sales reached AUD$4.2 million, an increase of 5% compared to the prior comparative period . Second quarter  global sales were AUD$2.2 million, up 11% on the previous quarter. In Australia, H1 sales totaled AUD$3.3 million, up 13% on pcp, with Q2 sales of AUD$1.7 million, an 11% increase on the prior quarter. The company also launched ProIBS in Australia during this period. In the USA, H1 sales were AUD$0.9 million, representing a 17% increase on pcp, with Q2 sales of AUD$0.4 million, up 8% from the previous quarter. Canadian H1 sales were AUD$56 thousand, down 85% on pcp, but Q2 sales rose to AUD$42 thousand, an increase of 191% on the prior quarter. Immuron anticipates further growth in Canada with the upcoming launch of Travelan in Jean Coutu pharmacies in Quebec.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IMC.AU":"IMMURON LTD","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK7508":"医药生物股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","BK7067":"生物科技"},"translate_title":"Immuron Limited报告上半年全球销售额增长5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"IMC.AU":0.9},"content_text":"Immuron Limited Reports 5% Increase in Global H1 Sales\n    \n\n        Immuron Limited has reported continued sales growth for the first half (H1) of the fiscal year. Global H1 sales reached AUD$4.2 million, an increase of 5% compared to the prior comparative period (pcp). Second quarter (Q2) global sales were AUD$2.2 million, up 11% on the previous quarter. In Australia, H1 sales totaled AUD$3.3 million, up 13% on pcp, with Q2 sales of AUD$1.7 million, an 11% increase on the prior quarter. The company also launched ProIBS® in Australia during this period. In the USA, H1 sales were AUD$0.9 million, representing a 17% increase on pcp, with Q2 sales of AUD$0.4 million, up 8% from the previous quarter. Canadian H1 sales were AUD$56 thousand, down 85% on pcp, but Q2 sales rose to AUD$42 thousand, an increase of 191% on the prior quarter. Immuron anticipates further growth in Canada with the upcoming launch of Travelan® in Jean Coutu pharmacies in Quebec.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9627699-en) on January 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}